At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 56 enrolled
Drug / intervention
Catapres-TTS-1 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind Study Designed to Assess the Bioequivalence and Adhesion Properties of Transdermal Clonidine-VistanexTM Compared to Transdermal Clonidine-Oppanol® Following Transdermal Administration in Healthy Male and Female Volunteers
In Brief
A Phase 1 clinical trial evaluating Catapres-TTS-1, Intervention 1: Catapres-TTS-3, and 1 other intervention for Healthy. Completed, enrolled 56 participants across 1 site.
Detailed Summary
To establish the bioequivalence and adhesion properties of transdermal clonidine prepared with Oppanol® brands of polyisobutylene (PIB) vs. transdermal clonidine prepared with VistanexTM brands of polyisobutylene (PIB) in healthy male and female volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
First PostedMar 2014
Primary CompletionJun 2014
TodayJul 2026
First PostedMar 26, 2014
Enrollment StartMar 1, 2014
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 12.3 years ago
Interventions
Catapres-TTS-1drug
Catapres-TTS-1 Oppanol
Intervention 1: Catapres-TTS-3drug
Catapres-TTS-3 Oppanol
Intervention 1: Catapres-TTS-3drug
Catapres-TTS-3 Oppanol
Intervention 2: Catapres-TTS-3drug
Catapres-TTS-3 Vistanex
Catapres-TTS-1drug
Catapres-TTS-1 Vistanex
Intervention 2: Catapres-TTS-3drug
Catapres-TTS-3 Vistanex